Business Context and Reporting Period
This Form 8-K filing by Dare Bioscience, Inc. (Dare) reports a material event occurring on April 24, 2018. The company entered into an Exclusive License Agreement with Juniper Pharmaceuticals, Inc. (Juniper) to acquire rights to certain patent technologies and processes.
Key Financial Metrics and Agreement Terms
The filing details the financial obligations associated with the Juniper License Agreement rather than reporting standard quarterly financial performance metrics such as revenue or net income.
- Upfront Fee: Dare paid a non-creditable upfront license fee of $250,000.
- Annual Maintenance Fees: $50,000 for the first two years, increasing to $100,000 thereafter. These fees are creditable against royalties due in the same calendar year.
- Milestone Payments: Potential future payments of up to $43.75 million per product or process (comprising up to $13.50 million in development milestones and up to $30.25 million in sales milestones).
- Royalties: Mid-single-digit to low double-digit percentages on worldwide net sales, or a low double-digit percentage of sublicense income.
Material Changes
The primary material change is the execution of the Exclusive License Agreement, which grants Dare exclusive, royalty-bearing worldwide rights to make, use, and sell products under Juniper's patent rights. This agreement introduces new contingent liabilities and future cash outflow obligations tied to development and sales milestones.
Outlook, Risks, and Contingencies
Management Commentary and Obligations: Dare is required to use commercially reasonable efforts to develop and make at least one product or process available to the public, adhering to specific diligence requirements.
Risks and Termination: Juniper may terminate the agreement for uncured payment breaches, failure to maintain insurance, insolvency, or material breach of other obligations. Dare may terminate on a country-by-country basis with 180 days' notice (or 90 days prior to U.S. marketing approval). Upon termination by Dare or for specific breaches by Juniper, Juniper retains access to product data generated by Dare.
Unusual Items: The filing notes that Dare will seek confidential treatment for certain terms of the agreement when the full text is filed in a future Form 10-Q.
Investor Verification Checklist
- Verify the specific patent rights and technologies covered under the Juniper License Agreement once the full text is filed.
- Monitor Dare's cash position to ensure it can meet the $250,000 upfront payment and future annual maintenance fees.
- Track the company's progress against the diligence requirements to avoid termination for failure to develop products.
- Assess the potential impact of the up to $43.75 million in milestone payments on future liquidity if development and sales targets are met.